



22 April 2022
EMA/CHMP/213286/2022
Committee for Medicinal Products for Human Use (CHMP)

Summary of opinion¹ (post authorisation)

NovoSeven

eptacog alfa (activated)

On 22 April 2022, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product NovoSeven. The marketing authorisation holder for this medicinal product is Novo Nordisk A/S.

The CHMP adopted a new indication for the treatment of severe postpartum haemorrhage. The full indications for NovoSeven will therefore be as follows:²

NovoSeven is indicated for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:

- in patients with congenital haemophilia with inhibitors to coagulation factors VIII or IX > 5 Bethesda Units (BU)
- in patients with congenital haemophilia who are expected to have a high anamnestic response to factor VIII or factor IX administration
- in patients with acquired haemophilia
- in patients with congenital FVII deficiency
- in patients with Glanzmann's thrombasthenia with past or present refractoriness to platelet transfusions, or where platelets are not readily available.

Severe postpartum haemorrhage

NovoSeven is indicated for the treatment of severe postpartum haemorrhage when uterotonics are insufficient to achieve haemostasis.

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), and will be available in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.

¹ Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion

² New text in **bold**

